{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04420884",
            "orgStudyIdInfo": {
                "id": "TAK-676-1002"
            },
            "secondaryIdInfos": [
                {
                    "id": "U1111-1241-4427",
                    "type": "REGISTRY",
                    "domain": "WHO"
                },
                {
                    "id": "2023-505627-30",
                    "type": "REGISTRY",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Takeda",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors",
            "officialTitle": "An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors",
            "acronym": "iintune-1",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-dazostinag-as-single-agent-and-dazostinag-in-combination-with-pembrolizumab-in-adults-with-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-07-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-06-04",
            "studyFirstSubmitQcDate": "2020-06-04",
            "studyFirstPostDateStruct": {
                "date": "2020-06-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Takeda",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of dazostinag are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck (SCCHN) and in combination with pembrolizumab in third-line or later recurrent locally advanced or metastatic microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and third-line recurrent locally advanced or metastatic microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal cancer (CRC).",
            "detailedDescription": "The drug being tested in this study is called dazostinag. Dazostinag is being tested to treat people who have advanced or metastatic solid tumors.\n\nThe study will enroll approximately 374 participants. Part 1 consists of an initial Safety Lead-in to Dose Escalation Phase; Part 2 and Part 3 compose the Expansion Phase in 2 specific indications namely, previously untreated metastatic or recurrent, unresectable SCCHN (Part 2) and third-line or later recurrent locally advanced or metastatic MSI-H/dMMR and third-line recurrent locally advanced or metastatic MSS/pMMR CRC (Part 3). Participants will be assigned to the following treatment groups in the respective Phases of the study:\n\n* Part 1 (Dose Escalation Phase): Safety Lead-in + Dazostinag single agent (SA) \\[Part 1A\\] Dazostinag 0.1 milligram (mg) in the Safety Lead-in followed by Dazostinag as escalating doses (0.2 mg and above) in Part 1A\n* Part 1B (Combination Dose Escalation Phase): Dazostinag as escalating doses (0.2 mg and above) + Pembrolizumab\n* Japan Safety Lead-in: Dazostinag SA 5.0 mg in the Safety Lead-in\u00b1 Pembrolizumab in Arms A and B. Additional dose levels of Dazostinag (such as 14.0 mg) in combination with pembrolizumab may be explored during the Japan safety lead-in considering recommended dose for expansion (RDE1) as 5.0 mg and dose optimization.\n\nOnce a safe dose is recommended from Part 1, participants of select advanced or metastatic solid tumors will receive dazostinag in below defined cohorts in the expansion phase:\n\n* Part 2A (SCCHN Combined Positive Score \\[CPS\\] \u2265 1 Dose Expansion Phase): Dazostinag + Pembrolizumab\\*\n* Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy\n* Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC\n* Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC\n\nThis multi-center trial will be conducted worldwide. The overall time to participate in this study is 62.9 months. Participants will make multiple visits to the clinic, including 30 days after last dose of study drug for a follow-up assessment. Participants in Parts 2 and 3 will be followed for survival for up to 12 months after the last dose of study drug."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Neoplasms"
            ],
            "keywords": [
                "Drug Therapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 374,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 (Monotherapy Dose Escalation Phase): Dazostinag Safety Lead-in + Dazostinag SA [Part 1A]",
                    "type": "EXPERIMENTAL",
                    "description": "Safety Lead-in: Dazostinag 0.1 mg, infusion, intravenously (IV), once weekly, on Days 1, 8 and 15 in 21-day treatment cycles.\n\nDazostinag SA Dose Escalation (Part 1A): Dazostinag single agent (SA), infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the Dazostinag SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in.",
                    "interventionNames": [
                        "Drug: Dazostinag"
                    ]
                },
                {
                    "label": "Part 1B (Combination Dose Escalation Phase): Dazostinag + Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag escalating doses (0.2 mg and above) in combination with pembrolizumab 200 mg, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycle. Pembrolizumab 200 mg will be administered 1 hour prior to Dazostinag once every 3 weeks (Q3W). The dosing will be initiated when at least two dose levels (DLs) of Part 1A have been evaluated.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Arm A: Japan Safety Lead-in Dazostinag + Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag 5.0 mg, infusion, IV, in Japanese participants with advanced or metastatic solid tumors on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab 200 mg administered Q3W, IV, on Day 1 in each 21-day cycle.\n\nAdditional dose levels of Dazostinag (such as 14.0 mg) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead-in.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Arm B: Japan Safety Lead-in Dazostinag Transitioned to Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag 5.0 mg, infusion, IV, as an SA once on Day 1 in Cycle 0 (cycle length=7 days) in Japanese participants with advanced or metastatic solid tumors based on confirmation of tolerability in Arm A. Following Cycle 0 (7 days), participants will be transitioned to the same dose level of dazostinag on Days 1, 8, and 15 of each 21-day cycle in combination with pembrolizumab administered Q3W, IV, on Day 1 in each 21-day cycle.\n\nAdditional dose levels of dazostinag (such as \u2265 7.0 mg) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead-in.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Part 2A (SCCHN CPS \u2265 1 Dose Expansion and Optimization Phase): Dazostinag + Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag 5.0 mg, infusion, IV, will be administered in participants with squamous cell carcinoma of head and neck (SCCHN) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag 5.0 mg, infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 milligrams per milli Liters per minute (mg/mL/minute) \\[AUC 5\\]) or cisplatin (100 milligrams per square meter \\[mg/m\\^2\\] Day 1 of each treatment cycle), and 5-fluorouracil (\\[5-FU\\]; 1000 mg/m\\^2 per day for 4 consecutive days) Q3W for up to 6 cycles.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab",
                        "Drug: Platinum",
                        "Drug: 5-fluorouracil"
                    ]
                },
                {
                    "label": "Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite instability-high /mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC",
                    "type": "EXPERIMENTAL",
                    "description": "Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W.",
                    "interventionNames": [
                        "Drug: Dazostinag",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Dazostinag",
                    "description": "Dazostinag intravenous infusion.",
                    "armGroupLabels": [
                        "Arm A: Japan Safety Lead-in Dazostinag + Pembrolizumab",
                        "Arm B: Japan Safety Lead-in Dazostinag Transitioned to Pembrolizumab",
                        "Part 1 (Monotherapy Dose Escalation Phase): Dazostinag Safety Lead-in + Dazostinag SA [Part 1A]",
                        "Part 1B (Combination Dose Escalation Phase): Dazostinag + Pembrolizumab",
                        "Part 2A (SCCHN CPS \u2265 1 Dose Expansion and Optimization Phase): Dazostinag + Pembrolizumab",
                        "Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy",
                        "Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC",
                        "Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC"
                    ],
                    "otherNames": [
                        "TAK-676"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab intravenous infusion.",
                    "armGroupLabels": [
                        "Arm A: Japan Safety Lead-in Dazostinag + Pembrolizumab",
                        "Arm B: Japan Safety Lead-in Dazostinag Transitioned to Pembrolizumab",
                        "Part 1B (Combination Dose Escalation Phase): Dazostinag + Pembrolizumab",
                        "Part 2A (SCCHN CPS \u2265 1 Dose Expansion and Optimization Phase): Dazostinag + Pembrolizumab",
                        "Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy",
                        "Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC",
                        "Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Platinum",
                    "description": "Carboplatin or Cisplatin intravenous infusion",
                    "armGroupLabels": [
                        "Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "5-fluorouracil",
                    "description": "5-fluorouracil intravenous infusion",
                    "armGroupLabels": [
                        "Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity",
                    "description": "A severity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living \\[ADL\\]); Grade 3 scales as Severe (severe or medically significant but not immediately life threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 scales as Life-threatening consequences, urgent intervention indicated, and Grade 5 scales as Death related to Adverse Event (AE).",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Number of Participants with Dose-Limiting Toxicities (DLTs)",
                    "description": "A DLT will be defined as any of the TEAEs, but not limited to, those that occur during Cycle 1 and are considered by the investigator to be at least possibly related to dazostinag as a SA or in combination with pembrolizumab. TEAEs meeting DLT definitions occurring in Cycle 2 or later will be considered in the determination of the RDE of dazostinag, both in the dazostinag SA and the combination with pembrolizumab arms. Toxicity will be evaluated according to NCI CTCAE version 5.0.",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations",
                    "timeFrame": "Up to approximately 54 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cmax: Maximum Observed Plasma Concentration for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: AUCt: Area Under the Concentration-time Curve From Time 0 to Time t for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: AUCinf: Area Under the Concentration-time Curve From Time 0 to Infinity for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: t1/2z: Terminal Disposition Phase Half-life for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CL: Total Clearance After Intravenous Administration for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Vss: Volume of Distribution at Steady State After Intravenous Administration for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CLR: Renal Clearance for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Percentage of Dose Excreted in Urine During 24 Hours After Dosing",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: CLR/CL%: Renal Clearance as Percentage of Total Clearance for Dazostinag",
                    "timeFrame": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Cycle 1 Days 1, 8 and 15: pre-infusion and at multiple time points (up to 24 hours) post-infusion and at Day 1 for further cycles up to 54 months (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation Phase: Percentage of Dose Excreted in Feces During 24 Hours After Dosing",
                    "timeFrame": "Dose Escalation Phase: Cycle 1 Day 1: from start of infusion and at multiple time points (up to 24 hours) post-infusion (Cycle length=21 days)"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Overall Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants who achieve confirmed complete response (cCR) + confirmed partial response (cPR) during the study in response-evaluable population. ORR will be assessed based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Disease Control Rate (DCR)",
                    "description": "DCR is defined as the percentage of participants who achieve cCR + cPR + stable disease (SD) greater than (\\>) 6 weeks during the study in response-evaluable population. The DCR will be assessed based on RECIST version 1.1.",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Duration of Response (DOR)",
                    "description": "DOR is the time from the date of first documentation of a cPR or better to the date of first documentation of progressive disease for responders (cPR or better). Responders without documentation of progressive disease will be censored at the date of last response assessment that is SD or better. DOR will be assessed based on RECIST version 1.1.",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Time to Response (TTR)",
                    "description": "TTR is defined as the time from the date of first dose administration to the date of first documented cPR or better by the investigator. TTR will be assessed based on RECIST version 1.1.",
                    "timeFrame": "Up to approximately 54 months"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline in Upregulation of Dazostinag-induced Stimulator of Interferon Genes (STING)",
                    "timeFrame": "Baseline up to Month 54"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline in T-cell Infiltration Upon Dazostinag Treatment",
                    "timeFrame": "Baseline up to Month 54"
                },
                {
                    "measure": "Dose Escalation, Japan Safety Lead-in, and Expansion Phases: Fold Change from Baseline of Genomic, Transcriptomic and Protein Expressions in Tumor Tissues",
                    "timeFrame": "Baseline up to Month 54"
                },
                {
                    "measure": "Expansion Phase Only: Progression-Free Survival (PFS)",
                    "description": "PFS is defined as the time from the date of first dose administration to the date of first documented disease progression or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Expansion Phase Only: Overall Survival (OS)",
                    "description": "OS is defined as the time from the date of first dose administration to the date of death.",
                    "timeFrame": "Up to approximately 24 months"
                },
                {
                    "measure": "Expansion Phase Only: OS Rate at 12 Months",
                    "description": "12-month OS rate is defined as the percentage of participants who are still alive at 12 months from their first dose administration.",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Phase Only: OS Rate at 6 Months",
                    "description": "6-month OS rate is defined as the percentage of participants who are still alive at 6 months from their first dose administration.",
                    "timeFrame": "Up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n2. Dazostinag SA (dose escalation Part 1A):\n\n   o With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to these therapies.\n3. Dazostinag in combination with pembrolizumab (dose escalation Parts 1B and Japan safety lead-in):\n\n   * With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to them, including:\n   * Tumors that have relapsed or are refractory to anti-programmed cell death ligand protein 1 (anti PD-(L)-1) therapy.\n   * Tumors that are naive to anti-PD-(L)-1 therapy.\n4. For expansion phase only:\n\n   * SCCHN (Part 2):\n   * Participants with histologically confirmed (cytological diagnosis is acceptable) metastatic or recurrent, unresectable SCCHN that is considered incurable by local therapies. Participants should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed more than 6 months before signing consent if given as part of multimodal treatment of locally advanced disease is allowed.\n   * Anatomic subsites to be included are oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, and paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal). The exception to this is nasopharyngeal cancer and salivary gland tumors, which will not be included.\n   * Participants with oropharyngeal cancer or tumors arising in the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal) must agree to provide archival tissue for human papilloma virus (HPV) testing or if known, HPV testing results (using CINtec\u00ae p16 Histology assay is preferred but not required) and a 70% cutoff point must be provided. Alternatively, archival tissue or a fresh excisional or core needle biopsy (\u2265 2 cores) is required for the determination of HPV status. If HPV status was previously tested using this method (CINtec\u00ae p16 Histology assay is preferred but not required), no additional testing is required. Archival tissue can be obtained up to 90 days prior to screening. Samples that are older than 90 days at screening may be used after consultation with the sponsor.\n   * For Part 2A, tumors must have a PD-L1 CPS \u2265 1. Participants must agree to provide fresh tumor biopsy for analysis from a core or excisional biopsy (fine needle aspirate is not sufficient) at screening for PD-L1 CPS assessment by a central laboratory. This specimen may be the diagnostic sample for participants with a new diagnosis of metastatic SCCHN. Participants for whom newly obtained samples cannot be obtained (eg, inaccessible or participant safety concern) may submit an archived specimen only upon agreement from the Sponsor. Archival tissue can be obtained up to 90 days prior to screening provided there was no other treatment from the time of biopsy until the start of study treatment. For Part 2B, any CPS is eligible but fresh or archival tissue is required for confirmation of CPS status. Collection of the tissue samples for PD-L1 assessments for Part 2B can be discontinued by the sponsor if sufficient data has been collected or dazostinag activity does not justify further collection.\n   * For Part 2B, participants must be eligible to receive treatment with either cisplatin or carboplatin in combination with 5-fluorouracil (5-FU) per the treating physician.\n5. CRC (Part 3):\n\n   * Third-line or later MSI-H/dMMR CRC (Part 3A): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSI-H/dMMR CRC whose disease has progressed on or following therapy with 1) an anti-PD-1 or PD-L1 antibody (i.e., pembrolizumab) and 2) at least one line of combination chemotherapy including a fluoropyrimidine and irinotecan OR oxaliplatin with or without an anti-epidermal growth factor receptor (EGFR) or anti-vascular endothelial growth factor (VEGFR) monoclonal antibody (i.e., cetuximab or bevacizumab). MSI-H/dMMR CRC participants must have received at least 6 weeks of prior treatment with an anti-PD-(L)-1 antibody. Only one line of anti-PD-(L)-1 is permitted.\n   * Third-line MSS/pMMR CRC (Part 3B): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSS/pMMR CRC whose disease has progressed on or following therapy with 2 different lines of combination chemotherapy, including therapy with a fluoropyrimidine and irinotecan AND therapy with a fluoropyrimidine and oxaliplatin. Both lines of therapy may be given with or without an anti-EGFR or anti-VEGFR monoclonal antibody (i.e., cetuximab or bevacizumab).\n\n   Participants with MSS/pMMR CRC must have progressed on or after combination chemotherapy regimens containing BOTH irinotecan AND oxaliplatin.\n   * Participants with MSI-H/dMMR or MSS/pMMR CRC must have documented MSI/MMR status assessed by a Clinical Laboratory Improvements Amendment-certified (United States \\[US\\] sites or an accredited (outside of the US) local laboratory using immunohistochemistry (IHC) and/or polymerase chain reaction (PCR) or next generation sequencing (NGS) assay.\n   * Adequate tumor tissue available for central laboratory confirmation of MSI/MMR status. Note: confirmation of central test positivity is not required before treatment.\n   * Participants with MSI-H/dMMR or MSS/pMMR CRC must have been treated with 2 prior lines of therapy in the recurrent locally advanced or metastatic setting.\n6. Adequate bone marrow, renal, hepatic and cardiac functions.\n7. Left ventricular ejection fraction (LVEF) \\> 50%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan within 4 weeks before receiving the first dose of study drug.\n8. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per NCI CTCAE Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.\n9. In dose escalation Part 1, (not applicable for the Japan safety lead-in) once peripheral evidence of dazostinag pharmacodynamic stimulation of the innate and/or adaptive immune system is observed in the blood and/or an imaging response/partial response (CR/PR) is observed in at least 1 participant, subsequent participants must:\n\n   * Have at least 1 lesion amenable for biopsy.\n   * Agree to have 2 tumor biopsies: 1 during the screening period and 1 while on dazostinag treatment.\n10. Must have at least 1 RECIST version 1.1-evaluable (measurable) lesion. For the dose escalation phase (Part 1) only, nonmeasurable only disease is acceptable.\n11. Pharmacokinetic (PK)/pharmacodynamic blood must be drawn on a peripherally-inserted catheter. Dazostinag is preferentially administered through a central line, but peripheral infusion is acceptable. If a peripheral line is used for dazostinag and/or pembrolizumab infusion, it must be separate than the one used for PK/pharmacodynamic collection.\n\nExclusion Criteria:\n\n1. Corrected QT interval by Fredericia (QTcF) greater than (\\>) 450 milliseconds (men) or \\> 475 milliseconds (women) on a 12-lead electrocardiogram (ECG) during the screening period.\n2. Grade greater than or equal to (\u2265) 2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during Cycle 0 Day 1 (C0D1) \\[for Japan safety lead-in only\\] and Cycle 1 Day 1 (C1D1) predose assessment.\n3. Oxygen saturation less than (\\<) 92 percent (%) on room air at screening or during C0D1 (for Japan safety lead-in only) and C1D1 predose assessment.\n4. Treated with other STING agonists/antagonist and toll-like receptors agonists within the past 6 months.\n5. Current history of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade \u2265 2 pleural effusion or ascites not controlled by tap or requiring indwelling catheters.\n6. History of brain and leptomeningeal metastasis unless:\n\n   * Brain metastases are clinically and radiologically stable or improved (that is, \u2265 4 weeks) following surgery, whole-brain radiation, or stereotactic radiosurgery, AND\n   * Off corticosteroids.\n7. Ongoing Grade \u2265 2 infection or participants with Grade \u2265 2 fever of malignant origin.\n8. Chronic, active hepatitis (example: participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus \\[HCV\\]- ribonucleic acid \\[RNA\\]).\n9. For participants in the dose escalation SA Part 1A only: refusal of standard therapeutic options.\n10. For participants receiving pembrolizumab only: contraindication and/or intolerance to the administration of pembrolizumab.\n11. For participants receiving chemotherapy in Part 2B: contraindication and/or intolerance to the administration of both platinum agents (cisplatin and carboplatin) and/or 5-FU.\n12. Participant has had any other prior or concurrent malignancy within 2 years prior to enrollment with the following exceptions: adequately treated localized basal cell or squamous cell carcinoma, or curatively treated in situ carcinoma of the cervix or breast. Other exceptions may be considered upon sponsor consultation.\n13. Concurrent chemotherapy (except for Part 2B), immunotherapy (except for pembrolizumab in Part 1B, Part 2, and Part 3), biologic, or hormonal therapy (except for adjuvant endocrine therapy for a history of breast cancer). Concurrent use of hormones for noncancer-related conditions is acceptable (except for corticosteroid hormones) unless allowed per exclusion criterion 16.\n14. Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible.\n15. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 7 days of C1D1 of study drug(s), with the following exceptions:\n\n    * Topical, intranasal, inhaled, ocular, intra-articular, and/or other non-systemic corticosteroids.\n    * Premedications required for computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n    * Physiological doses of replacement steroid therapy (example: for adrenal insufficiency).\n    * For participants enrolled in Part 2B, chemotherapy premedication with steroids can be administered according to local standards of care practice.\n16. Use of medications that are known clinical organic anion-transporting polypeptide B1 (OATP1B1) and/or OATP1B3 inhibitors, concurrently or within 14 days of C1D1 of study drug(s).\n17. Receipt of live attenuated vaccine (eg, tuberculosis Bacillus Calmette-Guerin vaccine, oral polio vaccine, measles, rotavirus, yellow fever) within 28 days of C1D1 of study drug(s).\n18. Recipients of allogeneic or autologous stem cell transplantation or organ transplantation.\n\n    For Part 2 SCCHN only:\n19. Has progressive disease (PD) within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN.\n20. Has a life expectancy of less than 3 months and/or has rapidly PD (eg, tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.\n21. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agent.\n22. Participants with known dihydropyrimidine dehydrogenase (DPD) deficiency or thymidine phosphorylase gene (TYMP) mutations (Part 2B only).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Takeda Contact",
                    "role": "CONTACT",
                    "phone": "+1-877-825-3327",
                    "email": "medinfoUS@takeda.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "Takeda",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California San Diego Moores Cancer Center",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92093",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "858-657-7000",
                            "email": "spatel@ucsd.edu"
                        },
                        {
                            "name": "Sandip Patel",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "Norris Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90089-1019",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "323-865-3967",
                            "email": "lenz@med.usc.edu"
                        },
                        {
                            "name": "Heinz-Josef Lenz",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "UCI Health - Chao Family Comprehensive Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "949-999-2400",
                            "email": "rrbanker@hs.uci.edu"
                        },
                        {
                            "name": "Rupali Nabar",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "University of California Los Angeles - Jonsson Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90404-2023",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "310-586-2094",
                            "email": "zwainberg@mednet.ucla.edu"
                        },
                        {
                            "name": "Zev Wainberg",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                },
                {
                    "facility": "SCRI - HealthOne Denver",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218-1238",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "720-754-2610",
                            "email": "gerald.falchook@scresearch.net"
                        },
                        {
                            "name": "Gerald Falchook",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Yale Cancer Center",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06519",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "203-785-3333",
                            "email": "patricia.lorusso@yale.edu"
                        },
                        {
                            "name": "Patricia LoRusso",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Memorial Cancer Institute at Memorial Hospital West - Cancer Institute/Radiology Oncology",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32610",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "352-265-0725",
                            "email": "jc.fabregas@ufl.edu"
                        },
                        {
                            "name": "Jesus Fabregas Mercado",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                },
                {
                    "facility": "Orlando Health Cancer Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32806",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "321-841-1147",
                            "email": "wasif.saif@orlandohealth.com"
                        },
                        {
                            "name": "Tirrell Johnson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Robert H. Lurie Comprehensive Cancer Center of Northwestern University",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "312-695-1300",
                            "email": "jochen.lorch@nm.org"
                        },
                        {
                            "name": "Jochen Lorch",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201-1544",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "410-328-7224",
                            "email": "ranee.mehra@umm.edu"
                        },
                        {
                            "name": "Ranee Mehra",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "617-724-4000",
                            "email": "xgao4@partners.org"
                        },
                        {
                            "name": "Xin Gao",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "877-442-3324",
                            "email": "jacob_sands@dfci.harvard.edu"
                        },
                        {
                            "name": "Jacob Sands",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201-2013",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "313-576-8778",
                            "email": "sukaria@karmanos.org"
                        },
                        {
                            "name": "Ammar Sukari",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Siteman Cancer Center - West County",
                    "status": "RECRUITING",
                    "city": "Creve Coeur",
                    "state": "Missouri",
                    "zip": "63141",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "314-747-8475",
                            "email": "dadkins@dom.wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.66089,
                        "lon": -90.42262
                    }
                },
                {
                    "facility": "Siteman Cancer Center - North County",
                    "status": "RECRUITING",
                    "city": "Florissant",
                    "state": "Missouri",
                    "zip": "63031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "314-747-8475",
                            "email": "dadkins@dom.wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.78922,
                        "lon": -90.32261
                    }
                },
                {
                    "facility": "Washington University School of Medicine Siteman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110-1032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "314-747-8475",
                            "email": "dadkins@dom.wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Siteman Cancer Center - South County",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63129",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "314-747-8475",
                            "email": "dadkins@dom.wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Siteman Cancer Center - St. Peters",
                    "status": "RECRUITING",
                    "city": "Saint Peters",
                    "state": "Missouri",
                    "zip": "63376",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "314-747-8475",
                            "email": "dadkins@dom.wustl.edu"
                        },
                        {
                            "name": "Douglas Adkins",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.80033,
                        "lon": -90.62651
                    }
                },
                {
                    "facility": "University of Cincinnati Health Barrett Cancer Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45019",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "513-558-2361",
                            "email": "sohalda@uc.edu"
                        },
                        {
                            "name": "Davendra Sohal",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "University of Cincinnati Health Barrett Cancer Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219-2354",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "513-558-2361",
                            "email": "sohalda@uc.edu"
                        },
                        {
                            "name": "Davendra Sohal",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "West Chester Hospital",
                    "status": "RECRUITING",
                    "city": "West Chester",
                    "state": "Ohio",
                    "zip": "45069",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "513-558-2361",
                            "email": "sohalda@uc.edu"
                        },
                        {
                            "name": "Davendra Sohal",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.23368,
                        "lon": -81.34428
                    }
                },
                {
                    "facility": "Providence Portland Medical Center",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "503-215-5696; 503-215-2614",
                            "email": "rachel.sanborn@providence.org; canrsrchstudies@providence.org"
                        },
                        {
                            "name": "Rachel Sanborn",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Fox Chase Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "215-214-1676",
                            "email": "anthony.olszanski@fccc.edu"
                        },
                        {
                            "name": "Anthony Olszanski",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "773-702-6180",
                            "email": "lukejj@upmc.edu"
                        },
                        {
                            "name": "Jason Luke",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute (SCRI)",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "615-329-7274",
                            "email": "meredith.pelster@scri.com"
                        },
                        {
                            "name": "Meredith Pelster",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "214-658-1994",
                            "email": "dorr@marycrowley.org"
                        },
                        {
                            "name": "Douglas Orr",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists, P.C. - Fairfax",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031-2171",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "304-293-4229",
                            "email": "mohamad.salkeni@usoncology.com"
                        },
                        {
                            "name": "Mohamad Salkeni",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Klinikum Wels-Grieskirchen",
                    "status": "RECRUITING",
                    "city": "Wels",
                    "state": "Oberoesterreich",
                    "zip": "4600",
                    "country": "Austria",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+4372424153451",
                            "email": "josef.thaler@klinikum-wegr.at"
                        },
                        {
                            "name": "Josef Thaler",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.16667,
                        "lon": 14.03333
                    }
                },
                {
                    "facility": "Landeskrankenhaus Salzburg",
                    "status": "RECRUITING",
                    "city": "Salzburg",
                    "zip": "5020",
                    "country": "Austria",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+4366244822879;+435725525",
                            "email": "r.greil@salk.at"
                        },
                        {
                            "name": "Richard Greil",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.79941,
                        "lon": 13.04399
                    }
                },
                {
                    "facility": "Landesklinikum Wiener Neustadt",
                    "status": "RECRUITING",
                    "city": "Wiener Neustadt",
                    "zip": "2700",
                    "country": "Austria",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+43 262 290 041 2801",
                            "email": "birgit.gruenberger@wienerneustadt.lknoe.at"
                        },
                        {
                            "name": "Birgit Grunberger",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.80484,
                        "lon": 16.23201
                    }
                },
                {
                    "facility": "Universitair Ziekenhuis Antwerpen",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Edegem",
                    "zip": "2650",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+32 3 821 36 46",
                            "email": "hans.prenen@uza.be"
                        },
                        {
                            "name": "Hans Prenen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.15662,
                        "lon": 4.44504
                    }
                },
                {
                    "facility": "Universitair Ziekenhuis Leuven - Campus Gasthuisberg",
                    "status": "RECRUITING",
                    "city": "Leuven",
                    "zip": "3000",
                    "country": "Belgium",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+32 1 634 42 18",
                            "email": "sabine.tejpar@uzleuven.be"
                        },
                        {
                            "name": "Sabine Tejpar",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                    }
                },
                {
                    "facility": "Cross Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1Z2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "7804328221",
                            "email": "michael.sawyer@albertahealthservices.ca"
                        },
                        {
                            "name": "Michael Sawyer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "McMaster University Medical Center",
                    "status": "RECRUITING",
                    "city": "Hamilton",
                    "state": "Ontario",
                    "zip": "L8N 3Z5",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 9055418115",
                            "email": "meyersbr@hhsc.ca"
                        },
                        {
                            "name": "Brandon Meyers",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.25011,
                        "lon": -79.84963
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "416-946-4534",
                            "email": "philippe.bedard@uhn.ca"
                        },
                        {
                            "name": "Philippe Bedard",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Jewish General Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "514-340-8222 x23460",
                            "email": "petr.kavan@mcgill.ca"
                        },
                        {
                            "name": "Petr Kavan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "McGill University Health Centre",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "514 3985 522",
                            "email": "nathaniel.bouganim@mail.mcgill.ca"
                        },
                        {
                            "name": "Nathaniel Bouganim",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Beijing Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "state": "Beijing Sheng",
                    "zip": "100142",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+861088196175; +86 10-88121122",
                            "email": "lin100@medmail.com.cn"
                        },
                        {
                            "name": "Lin Shen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                },
                {
                    "facility": "Sixth Affiliated Hospital of Sun Yat-Sen University/Guangdong Gastrointestinal Hospital",
                    "status": "RECRUITING",
                    "city": "Guangzhou",
                    "state": "Guangzhou Sheng",
                    "zip": "510655",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+86 20-38250745",
                            "email": "dengyanh@mail.sysu.edu.cn"
                        },
                        {
                            "name": "Yan-Hong Deng",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 23.11667,
                        "lon": 113.25
                    }
                },
                {
                    "facility": "Fudan University Shanghai Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Shanghai",
                    "state": "Shanghai",
                    "zip": "200025",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+86-18017312787",
                            "email": "jidongmei2000@hotmail.com"
                        },
                        {
                            "name": "Dongmei Ji",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.22222,
                        "lon": 121.45806
                    }
                },
                {
                    "facility": "Shanghai East Hospital",
                    "status": "RECRUITING",
                    "city": "Shanghai",
                    "state": "Shanghai",
                    "zip": "200123",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+8613501678472",
                            "email": "pattrickguo@gmail.com"
                        },
                        {
                            "name": "Ye Guo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.22222,
                        "lon": 121.45806
                    }
                },
                {
                    "facility": "West China School of Medicine - West China Hospital of Sichuan University",
                    "status": "RECRUITING",
                    "city": "Chengdu",
                    "state": "Sichuan Sheng",
                    "zip": "610610",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+86 18980601776",
                            "email": "qiumeng33@hotmail.com"
                        },
                        {
                            "name": "Meng Qiu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.66667,
                        "lon": 104.06667
                    }
                },
                {
                    "facility": "West China Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chengdu",
                    "state": "Sichuan",
                    "zip": "610041",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+86-18980606231",
                            "email": "32498600@qq.com"
                        },
                        {
                            "name": "Lei Liu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.66667,
                        "lon": 104.06667
                    }
                },
                {
                    "facility": "Zhejiang Cancer Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Hangzhou",
                    "state": "Zhejiang",
                    "zip": "310022",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+86-13750851650",
                            "email": "fangmy@zjcc.org.cn"
                        },
                        {
                            "name": "Meiyu Fang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.29365,
                        "lon": 120.16142
                    }
                },
                {
                    "facility": "Hopital Foch",
                    "status": "RECRUITING",
                    "city": "Suresnes",
                    "state": "Ile-de-France",
                    "zip": "92150",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "33240083333; 3314625200",
                            "email": "jaafar.bennouna@univ-nantes.fr"
                        },
                        {
                            "name": "Jaafar Bennouna-Louridi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.87143,
                        "lon": 2.22929
                    }
                },
                {
                    "facility": "Institut de Cancerologie de Lorraine",
                    "status": "RECRUITING",
                    "city": "Vand\u0153uvre-les-Nancy",
                    "state": "Meurthe-et-Moselle",
                    "zip": "54519",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 03 83 59 84 87",
                            "email": "c.gavoille@nancy.unicancer.fr"
                        },
                        {
                            "name": "Celine Gavoille",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.65,
                        "lon": 6.18333
                    }
                },
                {
                    "facility": "Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz",
                    "status": "RECRUITING",
                    "city": "Besancon",
                    "zip": "25000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33381668166;+33381479999",
                            "email": "christophe.borg@efs.sante.fr"
                        },
                        {
                            "name": "Christophe Borg",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.24878,
                        "lon": 6.01815
                    }
                },
                {
                    "facility": "Hopital Saint-Andre",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33556795808",
                            "email": "amaury.daste@chu-bordeaux.fr"
                        },
                        {
                            "name": "Amaury Daste",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "Centre Francois Baclesse",
                    "status": "RECRUITING",
                    "city": "Caen",
                    "zip": "14000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 2 31 45 50 02",
                            "email": "m.dossantos@baclesse.unicancer.fr"
                        },
                        {
                            "name": "Melanie Dos Santos",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.18585,
                        "lon": -0.35912
                    }
                },
                {
                    "facility": "Centre Georges Francois Leclerc",
                    "status": "RECRUITING",
                    "city": "Dijon",
                    "zip": "21079",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33380737506; +33380393353",
                            "email": "fghiringhelli@cgfl.fr"
                        },
                        {
                            "name": "Francois Ghiringhelli",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.31667,
                        "lon": 5.01667
                    }
                },
                {
                    "facility": "Centre de Lutte contre le Cancer - Centre Oscar Lambret",
                    "status": "RECRUITING",
                    "city": "Lille",
                    "zip": "59000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 320 295 954",
                            "email": "g-lefebvre@o-lambret.fr"
                        },
                        {
                            "name": "Gautier Lefebvre",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "Centre Leon Berard",
                    "status": "RECRUITING",
                    "city": "Lyon",
                    "zip": "69008",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33478785103",
                            "email": "jerome.fayette@lyon.unicancer.fr"
                        },
                        {
                            "name": "Jerome Fayette",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "Hopital de la Timone",
                    "status": "RECRUITING",
                    "city": "Marseille",
                    "zip": "13385",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33491385708",
                            "email": "sebastien.salas@ap-hm.fr"
                        },
                        {
                            "name": "Sebastien Salas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.29551,
                        "lon": 5.38958
                    }
                },
                {
                    "facility": "Hopital Saint-Antoine",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75012",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 149 282 954",
                            "email": "thierry.andre@aphp.fr"
                        },
                        {
                            "name": "Thierry Andre",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Institut de Cancerologie de lOuest - Saint-Herblain - Site Rene Gauducheau",
                    "status": "RECRUITING",
                    "city": "St Herblain",
                    "zip": "44805",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 01-42-41-28-25",
                            "email": "ludovic.doucet@ico.unicancer.fr"
                        },
                        {
                            "name": "Ludovic changed to Mallet, Amelie Doucet",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.21765,
                        "lon": -1.64841
                    }
                },
                {
                    "facility": "Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+33 1 4211 4617",
                            "email": "caroline.even@gustaveroussy.fr"
                        },
                        {
                            "name": "Caroline Even",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Soroka Medical Center",
                    "status": "RECRUITING",
                    "city": "Beer Sheva",
                    "zip": "9457108",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+972 086405407",
                            "email": "amichay@clalit.org.il"
                        },
                        {
                            "name": "Amichay Meirovitz",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.25181,
                        "lon": 34.7913
                    }
                },
                {
                    "facility": "Hadassah University Hospital Ein Kerem",
                    "status": "RECRUITING",
                    "city": "Jerusalem",
                    "zip": "9112001",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+972-50-9010225",
                            "email": "aron@hadassah.org.il"
                        },
                        {
                            "name": "Aron Popovtzer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Tel Aviv Sourasky Medical Center",
                    "status": "RECRUITING",
                    "city": "Tel Aviv-Yafo",
                    "zip": "64239",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+972 36974815; +9723-6394444",
                            "email": "ravitg@tlvmc.gov.il"
                        },
                        {
                            "name": "Ravit Geva",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "The Chaim Sheba Medical Center",
                    "status": "RECRUITING",
                    "city": "Tel Hashomer",
                    "zip": "52621",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+972 54 5542707",
                            "email": "ronen.stoff@sheba.gov.il"
                        },
                        {
                            "name": "Tamar Beller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.04195,
                        "lon": 34.85623
                    }
                },
                {
                    "facility": "National Cancer Center Hospital",
                    "status": "RECRUITING",
                    "city": "Chuo-Ku",
                    "state": "Tokyo",
                    "zip": "104-0045",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+81-3-3542-2511",
                            "email": "nbryamam@ncc.go.jp"
                        },
                        {
                            "name": "Yamamoto Noboru",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.57779,
                        "lon": 139.71685
                    }
                },
                {
                    "facility": "Centrum Onkologii Im. Prof. F. Lukaszczyka w Bydgoszczy",
                    "status": "RECRUITING",
                    "city": "Bydgoszcz",
                    "state": "Kujawsko-Pomorskie",
                    "zip": "85-796",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+48501446778;+48523743208",
                            "email": "bzur@wp.pl"
                        },
                        {
                            "name": "Bogdan Zurawski",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.1235,
                        "lon": 18.00762
                    }
                },
                {
                    "facility": "Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy",
                    "status": "RECRUITING",
                    "city": "Warsaw",
                    "state": "Mazowieckie",
                    "zip": "02-034",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+48 506159219; +480225462000",
                            "email": "lucjanwyrwicz@gmail.com"
                        },
                        {
                            "name": "Lucjan Wyrwicz",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "PRCCI Site: Puerto Rico Medical Research Center Torre Medica Hospital Auxilio Mutuo",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00917",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "787-900-5661; 787-296-8394",
                            "email": "jlozada@prmedcenter.com"
                        },
                        {
                            "name": "Jose Lozada-Costas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                },
                {
                    "facility": "Fundacion de Investigacion de Diego",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00927",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "787-722-1248",
                            "email": "macosta@fdipr.com"
                        },
                        {
                            "name": "Mirelis Acosta Riveli",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                },
                {
                    "facility": "PanOncology Trials: Universidad de Puerto Rico - Centro Comprensivo de Cancer",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00936",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "787-407-3333",
                            "email": "maria.garcia@panoncologytrials.com"
                        },
                        {
                            "name": "Maria Garcia-Pallas",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                },
                {
                    "facility": "Kantonsspital Sankt Gallen",
                    "status": "RECRUITING",
                    "city": "St. Gallen",
                    "state": "Saint Gallen",
                    "zip": "9007",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+410714942638",
                            "email": "dagmar.hess@kssg.ch"
                        },
                        {
                            "name": "Dagmar Hess-Mildenberger",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.42391,
                        "lon": 9.37477
                    }
                },
                {
                    "facility": "Inselspital Universitatsspital Bern",
                    "status": "RECRUITING",
                    "city": "Bern",
                    "zip": "3010",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+41 31 632 41 14",
                            "email": "martin.berger@insel.ch"
                        },
                        {
                            "name": "Martin D. Berger",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.94809,
                        "lon": 7.44744
                    }
                },
                {
                    "facility": "Hopitaux Universitaires de Geneve",
                    "status": "RECRUITING",
                    "city": "Geneve",
                    "zip": "1205",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+41 22-372-33-11",
                            "email": "thibaud.kossler@hcuge.ch"
                        },
                        {
                            "name": "Thibaud Koessler",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.20222,
                        "lon": 6.14569
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire Vaudois Lausanne",
                    "status": "RECRUITING",
                    "city": "Lausanne",
                    "zip": "1011",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "41 79 556 76 67",
                            "email": "petr.szturz@chuv.ch"
                        },
                        {
                            "name": "Petr Szturz",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.516,
                        "lon": 6.63282
                    }
                },
                {
                    "facility": "The Royal Marsden NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "state": "London",
                    "zip": "SM2 5NG",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+442086613158; +442073528171",
                            "email": "david.cunningham@icr.ac.uk"
                        },
                        {
                            "name": "David Cunningham",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                },
                {
                    "facility": "Queen's University Belfast",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Belfast",
                    "state": "Northern Ireland",
                    "zip": "BT9 7BL",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+44 289 097 2756",
                            "email": "v.coyle@qub.ac.uk"
                        },
                        {
                            "name": "Victoria Coyle",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.59682,
                        "lon": -5.92541
                    }
                },
                {
                    "facility": "Leeds Teaching Hospitals NHS Trust",
                    "status": "RECRUITING",
                    "city": "Leeds",
                    "zip": "LS9 7TF",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+44 113-243-3144",
                            "email": "f.j.collinson@leeds.ac.uk"
                        },
                        {
                            "name": "Fiona Collinson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.79648,
                        "lon": -1.54785
                    }
                },
                {
                    "facility": "University College London Hospitals NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "NW1 2BU",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+442034477210; +44 2079357700",
                            "email": "m.forster@ucl.ac.uk"
                        },
                        {
                            "name": "Martin Forster",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "The Royal Marsden NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "SW3 6JJ",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+442086613158; +442073528171",
                            "email": "david.cunningham@icr.ac.uk"
                        },
                        {
                            "name": "David Cunningham",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Oxford University Hospitals NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Oxford",
                    "zip": "Ox1 2JD",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Site Contact",
                            "role": "CONTACT",
                            "phone": "+44 01865 617411",
                            "email": "eileen.parkes@oncology.ox.ac.uk"
                        },
                        {
                            "name": "Eileen Parkes",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.75222,
                        "lon": -1.25596
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "To obtain more information on the study, click here/on this link",
                    "url": "https://clinicaltrials.takeda.com/study-detail/5f6b603d4db2bf003ab4a3a7"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "accessCriteria": "IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",
            "url": "https://vivli.org/ourmember/takeda/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000005472",
                    "term": "Fluorouracil"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "asFound": "According",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}